Akcea Therapeutics Steps Up Commercialization Efforts In Europe
Executive Summary
With one rare disease drug already available in Europe, and a second imminent, Akcea’s CEO outlined in a Scrip interview the European plans for this still-youthful US biotech.
You may also be interested in...
Akcea C-Suite Upheaval’s Reasons Unclear, Firm Set To Take In More Ionis Programs
Akcea terminates top three execs while praising their accomplishments in building up the Ionis spinout. Stock finished the trading day down nearly 20%.
EU CHMP Backs Three Conditional Approvals & Several Treatment Firsts
Akcea’s Waylivra, Portola’s Ondexxya, BioMarin’s Palynziq, AbbVie’s Skyrizi and Pfizer’s Lorviqua are among new drugs to receive a positive opinion from the EU’s CHMP at its latest monthly meeting.
Quiet Riot? Gene Silencing Candidates Still Ready To Make Noise In Lipid Disorders
Despite complete response letter for Akcea's Waylivra, RNA therapeutics may have regulatory pathway to approval for lipid disorders.